Clinical Trial Update: Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating the combination of oblimersen and gemtuzumab ozogamicin in older patients with relapsed acute myeloid leukemia; the study is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Genasense (oblimersen)
• Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: Genta Incorporated | Conditions: Leukemia | Phase 2 | Status: COMPLETED